This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by AstraZeneca Greece.
Reference
Tzanetakos C, et al. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece. Clinical Drug Investigation : 27 Oct 2017. Available from: URL: http://doi.org/10.1007/s40261-017-0586-0
Rights and permissions
About this article
Cite this article
Once-weekly exenatide in T2DM good value for money in Greece. PharmacoEcon Outcomes News 791, 19 (2017). https://doi.org/10.1007/s40274-017-4503-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4503-9